Millennium Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.51M | Sell |
20,758
-13,179
| -39% | -$2.28M | ﹤0.01% | 3319 |
|
|
2025
Q4 | $6.2M | Buy |
33,937
+28,196
| +491% | +$3.94M | ﹤0.01% | 2771 |
|
|
2025
Q3 | $697K | Sell |
5,741
-24,878
| -81% | -$2.8M | ﹤0.01% | 4870 |
|
|
2025
Q2 | $3.2M | Sell |
30,619
-204,692
| -87% | -$21.7M | ﹤0.01% | 3440 |
|
|
2025
Q1 | $27.4M | Buy |
235,311
+231,065
| +5,442% | +$26.3M | 0.01% | 1225 |
|
|
2024
Q4 | $359K | Sell |
4,246
-20,508
| -83% | -$1.89M | ﹤0.01% | 4969 |
|
|
2024
Q3 | $2.22M | Sell |
24,754
-715,065
| -97% | -$62.4M | ﹤0.01% | 3614 |
|
|
2024
Q2 | $59.6M | Sell |
739,819
-1,699
| -0.2% | -$126K | 0.03% | 698 |
|
|
2024
Q1 | $59.2M | Sell |
741,518
-168,447
| -19% | -$14.1M | 0.03% | 720 |
|
|
2023
Q4 | $72.4M | Buy |
909,965
+406,923
| +81% | +$27.2M | 0.03% | 572 |
|
|
2023
Q3 | $35.2M | Sell |
503,042
-232,061
| -32% | -$17.3M | 0.02% | 956 |
|
|
2023
Q2 | $52.8M | Sell |
735,103
-304,264
| -29% | -$22.4M | 0.03% | 704 |
|
|
2023
Q1 | $64.1M | Buy |
+1,039,367
| New | +$68.3M | 0.04% | 547 |
|
|
2022
Q4 | – | Sell |
-351,140
| Closed | -$15.7M | – | 6565 |
|
|
2022
Q3 | $15.7M | Buy |
351,140
+3,689
| +1% | +$184K | 0.01% | 1604 |
|
|
2022
Q2 | $13.3M | Buy |
347,451
+329,798
| +1,868% | +$10.4M | 0.01% | 1709 |
|
|
2022
Q1 | $731K | Sell |
17,653
-68,006
| -79% | -$2.11M | ﹤0.01% | 4818 |
|
|
2021
Q4 | $3.24M | Sell |
85,659
-51,666
| -38% | -$1.9M | ﹤0.01% | 3314 |
|
|
2021
Q3 | $4.53M | Sell |
137,325
-79,514
| -37% | -$3.1M | ﹤0.01% | 2963 |
|
|
2021
Q2 | $14.6M | Sell |
216,839
-19,324
| -8% | -$1.16M | 0.01% | 1499 |
|
|
2021
Q1 | $13.4M | Buy |
236,163
+87,205
| +59% | +$6.13M | 0.01% | 1490 |
|
|
2020
Q4 | $12.1M | Buy |
148,958
+46,639
| +46% | +$3.49M | 0.01% | 1530 |
|
|
2020
Q3 | $7.29K | Sell |
102,319
-54,935
| -35% | -$4.28M | 0.01% | 1519 |
|
|
2020
Q2 | $12.9M | Buy |
157,254
+4,923
| +3% | +$379K | 0.02% | 1037 |
|
|
2020
Q1 | $8.96M | Sell |
152,331
-352,407
| -70% | -$28.7M | 0.02% | 931 |
|
|
2019
Q4 | $52.2M | Buy |
504,738
+108,438
| +27% | +$4.38M | 0.07% | 350 |
|
|
2019
Q3 | $8.02M | Buy |
396,300
+6,784
| +2% | +$174K | 0.01% | 1433 |
|
|
2019
Q2 | $10M | Sell |
389,516
-374,458
| -49% | -$7.51M | 0.02% | 1248 |
|
|
2019
Q1 | $10.9M | Buy |
763,974
+455,172
| +147% | +$4.23M | 0.02% | 1189 |
|
|
2018
Q4 | $871K | Buy |
+308,802
| New | +$1.02M | ﹤0.01% | 2659 |
|
|
2018
Q1 | – | Sell |
-125,906
| Closed | -$705K | – | 3629 |
|
|
2017
Q4 | $705K | Sell |
125,906
-44,152
| -26% | -$223K | ﹤0.01% | 2915 |
|
|
2017
Q3 | $944K | Buy |
170,058
+10,098
| +6% | +$54.2K | ﹤0.01% | 2551 |
|
|
2017
Q2 | $880K | Buy |
159,960
+78,984
| +98% | +$331K | ﹤0.01% | 2506 |
|
|
2017
Q1 | $316K | Sell |
80,976
-3,829
| -5% | -$18.3K | ﹤0.01% | 3021 |
|
|
2016
Q4 | $572K | Buy |
+84,805
| New | +$596K | ﹤0.01% | 2619 |
|
|
2016
Q1 | – | Sell |
-55,809
| Closed | -$517K | – | 3255 |
|
|
2015
Q4 | $517K | Buy |
+55,809
| New | +$491K | ﹤0.01% | 2626 |
|
Other funds holding AXSM
VPM
VCM
DTC
Millennium Management's AXSM Position: Q1 2026 in Review
Millennium Management reduced its Axsome Therapeutics (AXSM) stake by 39% in Q1 2026, selling an estimated $2.28M and leaving 20,758 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3319.
Millennium Management first reported a position in AXSM in Q4 2015 and has held it in 35 quarters since. The position peaked at $72.4M in Q4 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Millennium Management held 20,758 shares of Axsome Therapeutics worth $3.51M as of Q1 2026.
- Millennium Management sold 13,179 Axsome Therapeutics shares in Q1 2026, an estimated $2.28M.
- Axsome Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3319 holding.
- Millennium Management first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 35 quarters since.
- Millennium Management's Axsome Therapeutics position peaked at $72.4M in Q4 2023.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.